A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-Squamous Non-Small Cell Lung Cancer · c-MET
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 854 (planned)
- Started
- Aug 3, 2025
- Main results expected
- Nov 2036
- Fully finished
- Nov 2036
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measured over: Up to Approximately 76 Months
Stage 2: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1.
Measured over: Up to Approximately 76 Months
Number of Participants with Adverse Events (AEs)
Measured over: Up to Approximately 76 Months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07005102 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC